UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Editas Medicine is implementing good security practices.
Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts which aims to develop therapies based on CRISPR–Cas9 gene editing technology. It was founded in 2013 with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures and licensed CRISPR patents from the Broad Institute's Feng Zhang, patents from Harvard's David Liu and George Church and patents from Partners Healthcare-MGH's J. Keith Joung.
This report shows a preliminary security rating for Editas Medicine. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.Get a deeper scan →
Read more about the latest issues in cybersecurity
DMARC (Domain-based Message Authentication, Reporting & Conformance) is an email authentication ...
Penetration testing, pen testing or ethical hacking, is the practice of testing a computer system, ...
Compare Editas Medicine's security performance with other companies